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Abstract In vitro, the heme cofactor of human iron(II) hemo-
globin was e⁄ciently and quickly alkylated at meso positions by
the peroxide-based antimalarial drug artemisinin, leading to
heme^artemisinin-derived covalent adducts. This reaction oc-
curred in the absence of any added protease or in the presence
of an excess of an extra non-heme protein, or even when arte-
misinin was added to hemolysed human blood. This activation of
artemisinin by the heme moiety of non-digested hemoglobin
clearly indicates the high a⁄nity of this drug for heme, and
its e⁄cient alkylating ability under very mild conditions.
# 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Plasmodium falciparum malaria is a major health scourge in
more than 90 countries and 40% of the global population is
vulnerable to this potentially deadly disease, due to global
resistance to the two most widely used antimalarial drugs,
chloroquine and the antifolate sulfadoxine/pyrimethamine.
Artemisinin and its hemisynthetic derivatives (artemether, ar-
teether and artesunate, which are all metabolized into dihy-
droartemisinin) have been increasingly used over the two past
decades in the treatment of multidrug-resistant P. falciparum
malaria. They are active against all malarial blood stages [1]
and induce a rapid clearance of the blood parasitemia. They
are also well tolerated and, to date, no signi¢cant resistance
has been reported either in clinical isolates or in laboratory
experiments. The combination of artemisinin derivatives with
conventional antimalarials with a longer half-life is increas-
ingly seen as a preferred way to e⁄ciently treat malaria while,
at the same time, minimizing the risk of developing drug re-
sistance [2,3].
Within red blood cells, Plasmodium parasites digest the host
hemoglobin to obtain amino acids to build their own proteins.
Then, to avoid the accumulation of the released and poten-
tially toxic iron(II)-heme, Plasmodia polymerize this redox-
active species as a microcrystalline, non-toxic, iron(III) poly-
mer, called hemozoin or malaria pigment. The reactivity of
the peroxide function of artemisinin with heme derivatives has
been considered a key factor to explain the pharmacological
activity of these endoperoxide drugs [4^7].
The mechanism of action of artemisinin derivatives involv-
ing the iron(II)-heme promoted reductive homolysis of the
peroxide function, and subsequent formation of drug-derived
C4-centered alkylating radicals has been documented [8]. The
alkylation of heme [9] was observed after incubation of phar-
macologically relevant concentrations of radiolabelled artemi-
sinin derivatives in cultured parasites, and we have recently
reported the complete characterization of the heme^artemisi-
nin adducts [10^12]. Under these conditions, heme is both the
trigger and the target of artemisinin. But maybe this mecha-
nism is not the only possible one [13]. Proteins are other
possible targets of the artemisinin-derived alkylating species
and the alkylation of speci¢c parasite proteins has also been
proposed [14,15], but no structure has been proposed up to
now for these protein^artemisinin adducts. It is noticeable
that this latter enzyme inhibition seems also to be dependent
on an iron(II)-mediated activation of artemisinin [15]. In this
alkylation of proteins by artemisinin, the trigger may be either
heme [14] or an unidenti¢ed reducing iron species [15], the
target being the close protein environment of these iron acti-
vators.
Beside the activation of artemisinin by heme itself, the al-
kylation of the heme residue of microperoxidase-11 (MP11, a
heme undecapeptide obtained by proteolytic digestion of cy-
tochrome c) has also been reported [16]. The heme moiety of
MP11 was found to be dialkylated by artemisinin, thus con-
¢rming the ability of artemisinin peroxide to be activated by
heme, even when linked to a small protein fragment. How-
ever, in MP11, heme is covalently bound to the peptide
through two thioether bonds, unlike hemoglobin. Since arte-
misinin is pharmacologically active on young stages of P.
falciparum, when hemoglobin is not yet extensively degraded,
it was necessary to investigate its reactivity with intact hemo-
globin or partly digested hemoglobin, provided that the heme
residues are still coordinated to a protein fragment. We report
here the e⁄cient alkylation at meso positions of the heme
residues of human ferrous hemoglobin A0 (OxyHb) in the
presence of artemisinin (only 1 mol equiv with respect to
heme) at 37‡C. This reaction occurs in the absence of any
added protease, or in the presence of an excess of an extra
non-heme protein, or even when artemisinin was added to
hemolysed whole human blood.
2. Materials and methods
2.1. Materials
OxyHb, pronase E (protease type XIV from Streptomyces griseus,
EC 3.4.24.31), trypsin (TPCK-treated from bovine pancreas, EC
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3.4.21.4), K-chymotrypsin (type I-S from bovine pancreas, EC
3.4.21.1), and all chemicals were purchased from Sigma-Aldrich.
High performance liquid chromatography (HPLC) analyses were
performed using a 5 Wm C4-QS-uptisphere 300 column, 250U4.6
mm (Interchim, France). Eluents were (A) 0.05 vol% tri£uoroacetic
acid in water, (B) 0.05 vol% tri£uoroacetic acid in acetonitrile. The
gradient was the following: from A/B=63/37 to A/B=52/48 in 30
min, then A/B=52/48 for 15 min. Flow rate was 1 ml/min, and UV
detection at 220 and 400 nm. Under these conditions, hemoglobin is
denatured and heme released from globins. Retention time (min): 12.0
(heme, Vmax = 398 nm), 15.4 (L-globin), 21.5 (K-globin), 22.7, 25.0,
26.9, 27.5 (four heme^drug adducts, relative ratio 1/3/3/3,
Vmax = 406^408 nm, Fig. 1).
2.2. Standard conditions for the reaction of hemoglobin with artemisinin
OxyHb (2.5 mg, 0.039 Wmol) was dissolved in CH3COONH4 10
mM, pH 8. Artemisinin (0.188 Wmol in 5 Wl dimethyl sulfoxide
(DMSO)) was then added. Final hemoglobin concentration was 300
WM, heme/artemisinin molar ratio= 1/1.2, and H2O/DMSO ratio= 96/
4 v/v. The solution was stirred and allowed to stand at 37‡C. After 1 h,
an aliquot (20 Wl) was injected for HPLC analysis. When speci¢ed, the
following changes were made: (i) CH3COONH4 10 mM, pH 8 was
replaced by CH3COONH4 10 mM, pH 6, or by (ii) H2O/NaOH, pH
8; (iii) the H2O/DMSO ratio varied from 99/1 to 1/1 v/v; (iv) gluta-
thione (GSH) was added: heme/GSH molar ratio= 1/10; (v) bovine
methemoglobin (MetHb) was used instead of OxyHb; (vi) bovine
serum albumin (BSA, 12.5 mg, OxyHb/BSA weight ratio= 1/5) was
added.
2.3. Reaction of OxyHb with artemisinin in the presence of a protease
OxyHb (2.5 mg, 0.039 Wmol) and pronase E, trypsin or K-chymo-
trypsin (0.125 mg) were dissolved in CH3COONH4 10 mM, pH 8 (125
Wl). After 1 h, artemisinin (0.188 Wmol in 5 Wl DMSO) and glutathione
(1.56 Wmol in 5 Wl water) were added and the reaction mixture was
kept at 37‡C for 1 h before HPLC analysis. Final hemoglobin con-
centration was 300 WM, heme/artemisinin/GSH molar ratio= 1/1.2/
10).
2.4. Reaction of artemisinin with human blood
Human blood (O+) was hemolysed just after withdrawal by addi-
tion of an equal amount of distilled water and centrifuged. An aliquot
of the supernatant (100 Wl) was further diluted with water (300 Wl),
artemisinin was added (0.625 Wmol in 18 Wl DMSO), and the mixture
was kept at 37‡C for 1 h before HPLC analysis. Final hemoglobin
concentration was 390 WM, heme/artemisinin molar ratio= 1/1.
3. Results and discussion
3.1. Hemoglobin and reaction medium
Normal OxyHb was used in ferrous state as con¢rmed by
its UV-visible spectrum, with characteristic absorbances at
542 and 576 nm (Soret at 412 nm, ammonium acetate 10
mM, pH 8) [17,18]. It was checked that OxyHb was stable
for several hours at room temperature, even in solution as
diluted as 5 WM. This is consistent with the reported slow
rate of deoxygenation (2^4 days) and the limited autoxidation
of oxyhemoglobin or oxymyoglobin solutions at pH 6^8
[17,19,20].
The interaction of artemisinin with hemoglobin was inves-
tigated in conditions that preserve the structure of hemoglo-
bin, at least that maintain the link of heme residues to the
globin chains. Ammonium acetate (10 mM) was reported to
be a non-denaturing medium at neutral pH, as it allowed mass
spectrometry analyses of hemoglobin with a low level of dis-
sociation of the Hb A0 tetramer, and a small content of apo-
K- and apo-L-globins [21,22], even with up to 20% of an
added organic cosolvent (methanol) [23]. However, artemisi-
nin is hydrophobic, nearly insoluble in water, but very soluble
in polar organic solvents such as methanol or DMSO. The
reaction of OxyHb with artemisinin was therefore performed
in a mixture of ammonium acetate (10 mM, pH 8) and
DMSO (or methanol), 96/4, v/v.
3.2. Reaction of OxyHb with artemisinin
In the presence of 1.2 mol equiv of artemisinin with respect
to heme residues of OxyHb, alkylation at K-, L-, Q- and N-
positions of heme occurred, giving rise to four isomeric cova-
lent adducts with overall yield of 31^33% (calculated per heme
residue). These heme^artemisinin adducts were identi¢ed by
comparison (HPLC and LC-MS, see Fig. 1) with reference
adducts previously characterized [12]. This alkylation reaction
resulted ¢rst from the hydrophobic interaction of artemisinin
with heme within the non-polar environment of the heme-
binding site, followed by the reductive homolysis of the per-
oxide function of artemisinin 1 by Fe(II)-heme 2, leading to
the addition of the artemisinin-derived C4 radical 3 onto the
porphyrin macrocycle (Scheme 1). The same products were
obtained with the same yield when using methanol (4 vol%)
instead of DMSO.
When OxyHb was replaced by MetHb, no modi¢cation of
the heme residues occurred, whereas alkylation of heme was
Fig. 1. Alkylation of OxyHb by artemisinin. HPLC and ESþ-MS
monitoring of the reaction.
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partly restored when MetHb was reduced by 10 molar equiv-
alents of glutathione or sodium ascorbate with respect to
heme, thus con¢rming the role of Fe(II) for the activation
of artemisinin. On the other hand, addition of glutathione
to OxyHb did not signi¢cantly change the alkylation reaction
(adduct yield: 29%).
3.3. Reaction of artemisinin with partly digested OxyHb
OxyHb was ¢rst exposed to pronase E, trypsin [24], or K-
chymotrypsin (5 wt%) at 37‡C and the decay of the globin
chains was monitored by HPLC. When the globin degrada-
tion was in the range of 10^40% (1^2 h), artemisinin and
glutathione were added (1.2 equiv and 10 equiv, respectively,
with respect to heme), and the mixture was allowed to stand
for 1 h at 37‡C. With K-chymotrypsin, the digestion of L- and
K-globins was 10% and 30%, respectively, and the yield of
heme alkylation was 24% when the reaction was performed
in CH3COONH4 (pH 8) with 4 vol% of DMSO. A similar
yield was obtained at pH 6 in the absence of glutathione, or
when CH3COONH4 was replaced by aqueous sodium hydrox-
ide pH 8 in the presence of 1 vol% or 20 vol% of DMSO
(yield 23%). No higher yields were obtained for heme alkyl-
ation when partial proteolysis was achieved using either tryp-
sin or pronase E.
3.4. Reaction of artemisinin with OxyHb in the presence of
serum albumin
In order to check the speci¢city of the artemisinin reaction
with hemoglobin, a large excess of BSA (OxyHb/BSA weight
ratio = 1/5) was added to the reaction medium (CH3COONH4
pH 6, and 4 vol% DMSO). This extra non-heme protein did
not induce any change in the heme alkylation yield.
3.5. Reaction of artemisinin with human whole blood
Artemisinin was added to an aliquot of hemolysed human
whole blood. After 1 h, HPLC analysis indicated that 22% of
the total heme content was alkylated as heme^artemisinin co-
valent adducts (25% when 10 equiv of glutathione were added
with respect to artemisinin).
As previously reported for ‘free’ heme itself, the heme res-
idues of hemoglobin are able to activate the peroxide function
of artemisinin, leading to the same characterized heme^arte-
misinin covalent adducts in yields as high as 22^33%, provid-
ing that the iron is in its reduced state. The mild reaction
conditions suggested that hemoglobin was not extensively
modi¢ed. Heme residues are not deeply buried and their hy-
drophobic sites, able to accommodate artemisinin, may ac-
count for this reactivity.
In the reported conditions, the heme alkylation yield did
not increase above 22^33%, actually, close to one alkylated
heme per hemoglobin tetramer. That may be due to the lim-
ited solubility of artemisinin in the highly aqueous reaction
mixture. The alkylation of one heme may also induce mod-
i¢cations of the conformation of the hemoglobin tetramer that
preclude further alkylation reaction.
However, these results clearly indicated that artemisinin has
a high a⁄nity for hemoglobin resulting in e⁄cient heme al-
kylation by the drug, even in whole blood where a lot of
components might disturb the interaction of artemisinin
with hemoglobin, and subsequently the activation of the
drug. But they do not allow us to draw de¢nitive conclusions
about the in vivo mode of action of artemisinin. Within the
digestive vacuole of P. falciparum, the sequential process of
hemoglobin degradation is initiated by aspartic proteases
called plasmepsins, one of which, plasmepsin I, starts to
cleave the hemoglobin K-chain between Phe-33 and Leu-34
[25]. Interestingly, the use of several usual non-parasitic pro-
teases did not make it possible to increase the yield of heme
alkylation by artemisinin. This feature may account for the
speci¢city of artemisinin reactivity toward Plasmodium com-
pared to healthy erythrocytes.
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